Compare Abbott Laboratories (ABT) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Meta Platforms Inc — how do they compare? Abbott Laboratories trades at $95.53 (market cap $166.94B), while Meta Platforms Inc trades at $604.23 (market cap $1.56T). The key difference: Meta Platforms Inc is far larger — about 9.3× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | META | |
|---|---|---|
Market Cap | $166.94B | $1.56T |
Sector | Health | Media |
52-Week High | $136.62 | $790.00 |
52-Week Low | $82.57 | $525.72 |
Enterprise Value | $193.69B | $1.57T |
Dividend Yield | 2.63% | 0.34% |
Volume | — | 24,093,972 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
META stock trades at $603.37, up 0.51% with a bullish technical signal. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $7.31 exceeding the $6.70 estimate. Revenue grew to $201.0B in 2025, with strong profitability margins. The company launched its Muse Spark AI model, driving positive sentiment, though it faces a youth addiction lawsuit in Massachusetts.
Outlook remains positive with a consensus price target of $826.50, implying significant upside. Key opportunities include AI monetization and revenue growth, while risks involve regulatory lawsuits and high capital expenditures. Analyst consensus is strongly bullish with 79% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
